Real-world survival after colorectal surgery for malignancy in Korean patients with chronic kidney disease: an analysis of Korean healthcare big data, 2002–2019open access
- Authors
- Inho Song; Hyeryeong Nam; Bora Lee; Byung Kwan Park; Jeong-ki Kim; Seung-Bum Ryoo; Kyu Joo Park; Eon Chul Han
- Issue Date
- Nov-2023
- Publisher
- 대한외과학회
- Keywords
- Chronic renal insufficiency; Colorectal neoplasms; Dialysis; Oncologic outcome; Survival
- Citation
- Annals of Surgical Treatment and Research, v.105, no.5, pp 281 - 289
- Pages
- 9
- Journal Title
- Annals of Surgical Treatment and Research
- Volume
- 105
- Number
- 5
- Start Page
- 281
- End Page
- 289
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/68636
- DOI
- 10.4174/astr.2023.105.5.281
- ISSN
- 2288-6575
2288-6796
- Abstract
- Purpose: Globally, chronic kidney disease (CKD) is common and has been associated with an increased risk of colorectal cancer (CRC). There is a dearth of literature on the real-world morbidity and mortality associated with CKD comorbid with CRC. This study was performed to evaluate real-world survival outcomes of colorectal malignancy in Korean CKD patients.
Methods: The National Health Insurance Service of Korea provided data on patients who underwent surgical resection among patients diagnosed with CRC from 2002 to 2019.
Results: A total of 219,550 patients were included: 6,181 patients with underlying CKD and 213,369 patients without it.
Each morbidity was significantly higher in the CKD-CRC group, and the postoperative mortality rates for the 30-day (3.11% vs. 1.78%, P < 0.001), 60-day (5.95% vs. 3.83%, P < 0.001), and 90-day mortality rate (8.12% vs. 5.32%, P < 0.001) were significantly higher in the CKD group. The median survival time (MST, year) was significantly lower in the CKD-CRC group (5.63; interquartile range [IQR], 5.26–5.91) than in the non-CKD-CRC group (8.71; IQR, 8.37–8.93). MST was significantly lower among CKD patients who received chemotherapy after adjustment by multivariate analysis (adjusted hazard ratio [HR], 1.43; 95% confidence interval [CI], 1.37–1.49; P < 0.001]). Subgroup analysis showed that in the CKD-CRC group, MST was lower in patients who received dialysis than in those who did not, even after multivariate analysis (adjusted HR, 2.38; 95% CI, 2.20–2.58; P < 0.001).
Conclusions: Prevention of CKD-to-end-stage renal disease progression should be adopted as a strategy to increase postoperative survival, along with active surveillance and cancer treatment.
- Files in This Item
-
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/68636)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.